Center for Internal Medicine I, University of Ulm, Ulm, Germany.
Laboratory for Protein Phosphorylation and Proteomics, Department of Cellular and Molecular Medicine, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.
Oncogene. 2018 Mar;37(10):1263-1278. doi: 10.1038/s41388-017-0052-8. Epub 2017 Dec 20.
Protein kinase D2 (PKD2) is a serine/threonine kinase that belongs to the PKD family of calcium-calmodulin kinases, which comprises three isoforms: PKD1, PKD2, and PKD3. PKD2 is activated by many stimuli including growth factors, phorbol esters, and G-protein-coupled receptor agonists. PKD2 participation to uncontrolled growth, survival, neovascularization, metastasis, and invasion has been documented in various tumor types including pancreatic, colorectal, gastric, hepatic, lung, prostate, and breast cancer, as well as glioma multiforme and leukemia. This review discusses the versatile functions of PKD2 from the perspective of cancer hallmarks as described by Hanahan and Weinberg. The PKD2 status, signaling pathways affected in different tumor types and the molecular mechanisms that lead to tumorigenesis and tumor progression are presented. The latest developments of small-molecule inhibitors selective for PKD/PKD2, as well as the need for further chemotherapies that prevent, slow down, or eliminate tumors are also discussed in this review.
蛋白激酶 D2(PKD2)是一种丝氨酸/苏氨酸激酶,属于钙调蛋白依赖性激酶 PKD 家族,该家族由三个同工型组成:PKD1、PKD2 和 PKD3。PKD2 可被多种刺激物激活,包括生长因子、佛波酯和 G 蛋白偶联受体激动剂。PKD2 在各种肿瘤类型中参与了不受控制的生长、存活、新生血管生成、转移和侵袭,这些肿瘤类型包括胰腺癌、结直肠癌、胃癌、肝癌、肺癌、前列腺癌和乳腺癌,以及多形性胶质母细胞瘤和白血病。本文从 Hanahan 和 Weinberg 描述的癌症特征的角度讨论了 PKD2 的多功能性。介绍了 PKD2 在不同肿瘤类型中的状态、受影响的信号通路以及导致肿瘤发生和肿瘤进展的分子机制。本文还讨论了针对 PKD/PKD2 的小分子抑制剂的最新进展,以及需要进一步的化疗来预防、减缓或消除肿瘤的必要性。